Unity Biotechnology, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Amortization of debt issuance costs
Debt extinguishment loss upon paydown of principal
Debt extinguishment gain upon conversion to equity
Net accretion and amortization of premium and discounts on marketable securities
Other expense related to the commitment shares issued to Lincoln Park Capital Fund
Gain on disposal of property and equipment
Stock-based compensation
Loss on disposal of property and equipment
Common stock issued to third parties
Non-cash rent expense
Impairment of long-lived assets
Change in fair value of strategic investment
Accretion of tenant improvement allowance
Change in fair value of contingent consideration
Gain on warrant liability
Extinguishment loss and Issuance costs on warrant
Changes in operating assets and liabilities:
Contribution receivable
Prepaid expenses and other current assets
Other long-term assets
Accounts payable
Accrued compensation
Accrued liabilities and other current liabilities
Other long-term liabilities
Derivative liability related to debt
Deferred revenue
Deferred rent, net of current portion

Net cash used in operating activities
Investing activities
Purchase of marketable securities
Maturities of marketable securities
Sale of property and equipment
Sale of strategic investments
Purchase of investment in stock
Purchase of property and equipment
Net cash provided by (used in) investing activities

Financing activities
Payment of debt principal
Payments made on capital lease obligations
Payment of debt issuance costs
Proceeds from issuance of convertible preferred stock, net of issuance costs
Proceeds from issuance of common stock, net of issuance costs
At The Market Equity Offering Program
Private Placement
Follow-on Offering
Warrant Inducement Agreement
Lincoln Park Capital Fund Equity Purchase Agreement
Total proceeds from issuance of common stock, net of issuance costs

Issuance costs for sale of common stock
Proceeds from repayment of recourse notes
Proceeds from repayment of employee promissory notes
Proceeds from long-term debt, net of issuance costs to lender
Proceeds from issuance of common stock upon exercise of stock options, net of repurchases
Proceeds from issuance of common stock under the 2018 ESPP
Proceeds from initial public offering, net of issuance costs
Current portion of long-term debt arrangement
Net cash provided by (used in) financing activities

Net increase (decrease) in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of year
Cash, cash equivalents and restricted cash at end of year
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest
Supplemental Disclosures of Non-Cash Investing and Financing Activities
Issuance of common shares in payment of debt
Property and equipment included in accounts payable
Issuance of common stock in settlement of contingent consideration milestone
Issuance of shares in settlement of share-based liability
Right-of-use assets obtained in exchange for new operating lease liabilities
Lessor funded lease incentives included in property and equipment
Receipt of promissory note for purchase of common stock
Receipt of promissory note from related party for purchase of common stock

Comments